Tokyo, Japan
Tokyo, Japan

Fujifilm Holdings Corporation, commonly known as Fujifilm, is a Japanese multinational photography and imaging company headquartered in Tokyo, Japan.Fujifilm's principal activities are the development, production, sale and servicing of color film, digital cameras, photofinishing equipment, color paper, photofinishing chemicals, medical imaging equipment, graphic arts equipment and materials, flat panel displays, optical devices, photocopiers and printers. Wikipedia.


Time filter

Source Type

An insertion needle 15 has a photoacoustic wave generating portion that generates a photoacoustic wave by absorbing light emitted from a laser unit 13. A photoacoustic image generation unit 25 generates a photoacoustic image based on the detection signal of the photoacoustic wave emitted from the insertion needle 15. The sound source position detection unit 30 detects the photoacoustic wave generating source from the photoacoustic image. A first signal acquisition unit 31 acquires an S value, and a second signal acquisition unit 32 acquires an N value. A light emission control unit 33 controls the number of light emissions and the light emission interval of the laser unit 13 for one photoacoustic image generation based on the ratio between the S value and the N value. The photoacoustic image generation unit 25 generates a photoacoustic image by at least adding the detection signals of photoacoustic waves corresponding to the number of light emissions.


An image obtaining unit obtains actual endoscope images, and a virtual endoscope image generating unit generates virtual endoscope images including a plurality of virtual endoscope branch images. A corresponding virtual endoscope image determining unit obtains a plurality of actual endoscope images which were obtained within a predetermined amount of time before the endoscope reached its current position, compares the plurality of actual endoscope images and the plurality of virtual endoscope branch images, and determines a corresponding virtual endoscope image that corresponds to the branch structure closest to the current position of the endoscope, through which the endoscope has passed. A matching unit performs matching between each of a plurality of actual endoscope path images and a plurality of virtual endoscope path images for each of a plurality of paths. A position identifying unit identifies the current position of a leading end of the endoscope based on the results of matching.


Patent
Fujifilm Co. | Date: 2016-11-07

An endoscope includes a first flat surface formed at a distal end portion of an insertion part to be inserted into a subject, and orthogonal to an axial direction of the insertion part, an observation window provided at the distal end portion for allowing image light of the subject to be taken therethrough, with a surface of the observation window as a light incidence plane, an illumination window provided at the distal end portion to irradiate a subject with illumination light, a fluid jetting nozzle arranged at the first flat surface to jet a fluid toward the observation window and fixed at the distal end portion of the insertion part, and an inclined surface formed around the observation window and arranged at a position that faces the fluid jetting nozzle.


An image obtainment unit obtains a radiographic image radiographed by irradiating a subject with radiation. A first information obtainment unit obtains information about at least one of a radiography condition during radiography of the subject, a subject condition and detector characteristics, which are characteristics of the radiation detector. A second information obtainment unit obtains body thickness information representing the body thickness of the subject. A target S/N setting unit sets a target S/N of the radiographic image based on the body thickness information and the information about at least one of the radiography condition, the subject condition and the detector characteristics. An image processing unit corrects the S/N of the radiographic image to the target S/N by performing, on the radiographic image, noise removal processing.


Grant
Agency: Cordis | Branch: H2020 | Program: IA | Phase: NMP-24-2015 | Award Amount: 7.95M | Year: 2016

Shortage of fresh water has become one of the major challenges for societies all over the world. Water desalination offers an opportunity to significantly increase the freshwater supply for drinking, industrial use and irrigation. All current desalination technologies require significant electrical or thermal energy, with todays Reverse Osmosis (RO) desalination units consuming electric energy of at least 3 kWh/m3 in extensive tests about ten years ago, the Affordable Desalination Collaboration (ADC) in California measured 1.6 kWh/m3 for RO power consumption on the best commercially available membranes, and total plant energy about twice as high. To overcome thermodynamical limitations of RO, which point to 1.09 kwh/m3 for seawater at 50 % recovery, Microbial Desalination Cells (MDC) concurrently treat wastewater and generate energy to achieve desalination. MDCs can produce around 1.8 kWh of bioelectricity from the handling of 1 m3 of wastewater. Such energy can be directly used to i) totally remove the salt content in seawater without external energy input, or ii) partially reduce the salinity to lower substantially the amount of energy for a subsequent desalination treatment. MIDES aims to develop the Worlds largest demonstrator of an innovative and low-energy technology for drinking water production, using MDC technology either as stand-alone or as pre-treatment step for RO. The project will focus on overcoming the current limitations of MDC technology such as low desalination rate, high manufacturing cost, biofouling and scaling problems on membranes, optimization of the microbial-electrochemical process, system scaling up and economic feasibility of the technology. This will be achieved via innovation in nanostructured electrodes, antifouling membranes (using nanoparticles with biocide activity), electrochemical reactor design and optimization, microbial electrochemistry and physiology expertise, and process engineering and control.


Grant
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: LCE-01-2014 | Award Amount: 4.13M | Year: 2015

The concept is based on the generation of electricity from salinity gradient using Reverse Electrodialysis with artificial saline solutions operating in a closed-loop. The original salinity gradient is regenerated by a separation step that uses heat at 40 - 100 C. The regenerated solutions can be stored at very low costs and the stack can react within seconds, providing flexibility to the power system. It is a quiet technology operating under normal pressures and temperatures imposing no risks. The industrial partners ensures the MRL will be kept aligned with the advances in TRL. The overall objective is to prove this revolutionary concept, develop the necessary materials, components and know-how for bringing it to the level of a lab prototype generating electricity from low-grade heat at higher efficiencies and lower costs than ever achieved to date. Specific objectives: Select the most suitable technologies for the regeneration process and the combinations of salts and solvents that can maximise the system performance. Create new knowledge for developing: membranes for the selected solutions; membrane manufacturing concepts that can be scaled-up for high volume and low-cost production; efficient stacks suitable for this application; energy efficient regeneration processes. Implement and validate a process simulation tool to analyse the performance under different configurations and operating conditions. Evaluate and improve the performance of the overall system through tests on a lab-prototype, identifying potential up-scaling and operational issues (System efficiencies reaching 15% and power densities of 25 W/m2 of cell pair). Define a development roadmap, taking into account environmental, social and regulatory issues, leading to levelised cost of electricity below 0.03 Euro/kWh by 2025 to 2030. Involve target group representatives to the Advisory Board and communicate the key results in order to initiate a dialogue and facilitate the engagement of key actors.


Grant
Agency: Cordis | Branch: H2020 | Program: IA | Phase: NMP-24-2015 | Award Amount: 9.80M | Year: 2016

The REvivED water project will establish electrodialysis (ED) as the new standard providing a source of safe, affordable, and cost-competitive drinking water, using less than half the energy required by state-of-the-art Reverse Osmosis (RO) plants. The innovations of the project constitute a technology platform with a very wide field of potential applications. All components and systems have reached at least TRL4 and will be further developed reaching at least TRL7. The main focus of the project will be on the following applications: 1. A simplified ED system that can be used for brackish water desalination (8 pilots in developing countries) or for tap-water softening (2 pilots in Germany and the Netherlands). 2. A multistage ED system for industrial-scale seawater desalination, which will be demonstrated to reach energy consumption as low as 1.5 kWh/m3 (1 pilot in the Netherlands). 3. Combinations of the multistage ED system with the latest salinity gradient power systems (Reverse ElectroDialysis - RED), which can further reduce energy consumption for seawater desalination to the region of 1 kWh/m3 (1 pilot in the Netherlands). 4. The versatile nature of the developed innovations will be demonstrated by testing their combinations with Reverse Osmosis (RO) systems (1 pilot in Spain). This will allow initial market introduction, without the need to replace the extensive RO infrastructure. The pilot systems in developing countries will be located in critical areas where the project partner PHAESUN has local offices in Africa (Eritrea, Ivory Coast, Somalia, Djibouti and Ethiopia), Asia (Dubai, and India) and Latin America (Panama). The consortium brings together leading partners covering the whole value chain and ensuring exploitation of the results. It is clearly industry driven, and it gives European industry the chance to take the lead of the ED revival and face the competition from the US that is also actively pursuing this important growth market.


Grant
Agency: Cordis | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2014-ETN | Award Amount: 4.04M | Year: 2015

Reducing lead times of new medicinal drugs to the market by reducing process development and clinical testing timeframes is a critical driver in increasing European (bio)pharmaceutical industry competitiveness. Despite new therapeutic principles (e.g. the use of pluripotent stem cells, regenerative medicine and treatments based on personalised medicine or biosimilars) or regulatory initiatives to enable more efficient production, such as Quality by design (QbD) with associated Process Analytical Technology (PAT) tools , the slow progress in the development of new bioactive compounds still limits the availability of cheap and effective medicines. In addition, the competitiveness of European (bio)pharma industry is impacted by the unavailability of suitably trained personnel. Fundamental changes in the education of scientists have to be realised to address the need for changes in the traditional big pharma business model and the focus on translational medicine more early stage clinical trials with patients, more external innovation and more collaboration. These changes in education should be based on combining cutting-edge science from the early stage of product development through to manufacturing with innovation and entrepreneurship as an integral part of the training. The Rapid Bioprocess Development ITN, employing 15 ESRs, brings together industrialist and academic experts with its main aim to address this critical need by developing an effective training framework in rapid development of novel bioactive molecules from the very early stages of potency and efficacy testing to the biomanufacturing process characterisation and effective monitoring. The main focus of the research is on oncology related proteins and recombinant proteins to be used in diabetes treatment, although the resulting monitoring and modelling methods will be applicable to other bioactive molecule process development as demonstrated by validation on a range of relevant bioactives.


Grant
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: FETOPEN-1-2014 | Award Amount: 3.53M | Year: 2016

Separation and purification of biopharmaceuticals is today one of the most time and cost intense Downstream Processing (DSP) operations in the manufacture of commercial products. Separation and purification of proteins is usually achieved chromatographically, with all of its disadvantages including high buffer requirements, large footprint, reuse and storage of resin studies as well as costs. Traditional DSP based on batch chromatography contribute ca. 66% of the total production cost of anti-cancer monoclonal antibodies (mAbs). Largely contributing to this is the cost of chromatography media; for instance, the cost of 1 L of protein A resin with binding capacity of 20-70 g mAb is about 25000 Eur. By a visionary and ambitious combination of the emerging Continuous Manufacturing Paradigm with innovative Membrane Crystallization Technology and the selective nanotemplate-recognitions directly from the fermentation broth, the AMECRYS Network aims to develop a new Continuous Template-Assisted Membrane Crystallizer in order to revolutionize the DSP platform for mAbs production, thus achieving unprecedented purification and manufacturing efficiencies. Major research challenges will include: i) the synthesis of 3D-nanotemplates with specific molecular recognition ability towards mAbs from complex solutions; ii) the development of tailored macroporous fluoropolymer membranes for advanced control of selective heterogeneous nucleation; iii) the design of multilevel microfluidic devices for high-throughput mAb crystallization screening in a wide range of conditions under continuous flow (pharma-on-a-chip concept); iv) technology scale-up to a L-scale continuous prototype designed with recognition of QS/GMP compliance for biopharmaceuticals. The replacement of chromatography with a single membrane-crystallization unit will lead to >60% CapEx and O&M costs decrease, 30-fold footprint reduction and high-purity solid formulation of mAbs with preserved biological activity.


Grant
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: LCE-24-2016 | Award Amount: 4.99M | Year: 2016

Membrane separation processes can be applied to many capture processes from Pre-Combustion ( CO2-H2 / CO2-CH4 separation) to Post-Combustion (CO2-N2) and Oxyfuel (O2-N2) and are generally endowed with high flexibility and potentially low operative costs with respect to other capture methods. However the current materials are still lacking of separation performance and durability suitable for an efficient and economically feasible exploitation of such technology. The Project NANOMEMC2 aims in overcoming the current limitation focusing on the development of innovative CO2 selective membranes with high flux and selectivity suitable for application to both Pre and Post-combustion Capture processes. To that aim nanocomposite or mixed matrix membranes will be considered with particular focus on facilitated transport mechanisms promoted by carrier attached to the polymer or the filler. Graphene based nanosheets and cellulose nanofibres will be studied in detail considering their possible modification to improve polymer compatibility and affinity with CO2. A new generation of Facilitated Transport Mixed Matrix ( FTMM) membranes for CCS applications will be developed with increased CO2 flux and selectivity beyond the current target for industrial deployment of carbon capture membrane technologies

Loading Fujifilm Co. collaborators
Loading Fujifilm Co. collaborators